Collaborations

Research alliance with Merck targets

Published in Cancer Weekly, November 18th, 2003

Celera Diagnostics, a joint venture between the Celera Genomics Group (CRA) and Applied Biosystems Group (ABI) of Applera Corporation, announced that it has entered into a research collaboration with Merck & Co., Inc., to identify and validate genetic markers useful in the development of prognostic tests and therapeutics for selected cancers.

The agreement provides Celera Diagnostics access to certain gene expression data and intellectual property of Merck through its wholly owned subsidiary, Rosetta Inpharmatics LLC. It also provides Merck access to selected research data from Celera Diagnostics for use in developing cancer therapeutics. While the collaboration is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-11-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry